A Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin for Deep Vein Thrombosis (DVT) Treatment in Ethiopia
Manaye Tamrie Derseh,1 Kiflom Solomon,2 Wasihun Tamene,3 Wosenie Beneberu,3 Ashagrachew Tewabe Yayehrad,4 Abyou Seyfu Ambaye1 1Departement of Pharmaceutics and Social Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, Mizan-Tepi University, Mizan-Aman, Ethiopia; 2Ayder Teaching H...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-09-01
|
| Series: | ClinicoEconomics and Outcomes Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/a-cost-effectiveness-analysis-of-rivaroxaban-compared-to-warfarin-for--peer-reviewed-fulltext-article-CEOR |
| _version_ | 1824009643752423424 |
|---|---|
| author | Derseh MT Solomon K Tamene W Beneberu W Yayehrad AT Ambaye AS |
| author_facet | Derseh MT Solomon K Tamene W Beneberu W Yayehrad AT Ambaye AS |
| author_sort | Derseh MT |
| collection | DOAJ |
| description | Manaye Tamrie Derseh,1 Kiflom Solomon,2 Wasihun Tamene,3 Wosenie Beneberu,3 Ashagrachew Tewabe Yayehrad,4 Abyou Seyfu Ambaye1 1Departement of Pharmaceutics and Social Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, Mizan-Tepi University, Mizan-Aman, Ethiopia; 2Ayder Teaching Hospital, College of Health Sciences, Mekelle University, Mekelle, Ethiopia; 3Tikur Anbessa Comprehensive Specialized Hospital (TASH), Federal Ministry of Health (FMOH), Addis Ababa, Ethiopia; 4Department of Pharmacy, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, EthiopiaCorrespondence: Manaye Tamrie Derseh Tel +251 921 79 15 97Email manayetamire@gmail.comBackground: Deep vein thrombosis and pulmonary embolism are known by the collective name venous thromboembolism. Deep vein thrombosis is the third most common cardiovascular disorder in the world. The disease is also prevalent in Africa including Ethiopia, besides lack of studies that show epidemiology of the disease.Objective: To assess cost effectiveness of rivaroxaban compared to warfarin-based therapy for deep vein thrombosis patients in Ethiopia.Methods: A Markov model was built to compare cost and effectiveness of rivaroxaban 15mg bid for three weeks and 20mg per day for the rest to adjusted dose of warfarin for one year using a restricted societal perspective. The population in this analysis was a hypothetical cohort of deep vein thrombosis patients 40 years old with no contraindication, comorbidity and concomitant therapy. The patients were followed yearly for 24 years up to their average life expectancy.Results: Rivaroxaban therapy resulted in higher quality adjusted life years with a value of 16.78, while warfarin-based treatment resulted in 16.34 quality adjusted life years. Total lifetime costs were $988.58 for rivaroxaban and $932.92 for unfractionated heparin/warfarin. Therefore, rivaroxaban resulted in a gain of 0.443 quality adjusted life years at an additional cost of $55.661. The incremental cost effectiveness ratios for rivaroxaban compared with warfarin was $125.683 per quality adjusted life year saved which is less than willingness to pay threshold of $783 per quality adjusted life year saved. Warfarin resulted in a net monetary benefit of $11,859.72, while that of rivaroxaban is $12,150.82, meaning rivaroxaban is cost-effective. Sensitivity analyses found that the model was sensitive to utility of no deep vein thrombosis, effectiveness of rivaroxaban and cost of rivaroxaban respectively.Conclusion: This study showed that rivaroxaban is a cost effective alternative and substituting rivaroxaban for warfarin is acceptable to willingness to pay threshold.Keywords: cost effectiveness, DVT, rivaroxaban, warfarin, Ethiopia |
| first_indexed | 2024-12-18T21:13:04Z |
| format | Article |
| id | doaj.art-cdd208935f5d4a979a53d17c350977b5 |
| institution | Directory Open Access Journal |
| issn | 1178-6981 |
| language | English |
| last_indexed | 2024-12-18T21:13:04Z |
| publishDate | 2021-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | ClinicoEconomics and Outcomes Research |
| spelling | doaj.art-cdd208935f5d4a979a53d17c350977b52022-12-21T20:52:28ZengDove Medical PressClinicoEconomics and Outcomes Research1178-69812021-09-01Volume 1382183468881A Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin for Deep Vein Thrombosis (DVT) Treatment in EthiopiaDerseh MTSolomon KTamene WBeneberu WYayehrad ATAmbaye ASManaye Tamrie Derseh,1 Kiflom Solomon,2 Wasihun Tamene,3 Wosenie Beneberu,3 Ashagrachew Tewabe Yayehrad,4 Abyou Seyfu Ambaye1 1Departement of Pharmaceutics and Social Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, Mizan-Tepi University, Mizan-Aman, Ethiopia; 2Ayder Teaching Hospital, College of Health Sciences, Mekelle University, Mekelle, Ethiopia; 3Tikur Anbessa Comprehensive Specialized Hospital (TASH), Federal Ministry of Health (FMOH), Addis Ababa, Ethiopia; 4Department of Pharmacy, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, EthiopiaCorrespondence: Manaye Tamrie Derseh Tel +251 921 79 15 97Email manayetamire@gmail.comBackground: Deep vein thrombosis and pulmonary embolism are known by the collective name venous thromboembolism. Deep vein thrombosis is the third most common cardiovascular disorder in the world. The disease is also prevalent in Africa including Ethiopia, besides lack of studies that show epidemiology of the disease.Objective: To assess cost effectiveness of rivaroxaban compared to warfarin-based therapy for deep vein thrombosis patients in Ethiopia.Methods: A Markov model was built to compare cost and effectiveness of rivaroxaban 15mg bid for three weeks and 20mg per day for the rest to adjusted dose of warfarin for one year using a restricted societal perspective. The population in this analysis was a hypothetical cohort of deep vein thrombosis patients 40 years old with no contraindication, comorbidity and concomitant therapy. The patients were followed yearly for 24 years up to their average life expectancy.Results: Rivaroxaban therapy resulted in higher quality adjusted life years with a value of 16.78, while warfarin-based treatment resulted in 16.34 quality adjusted life years. Total lifetime costs were $988.58 for rivaroxaban and $932.92 for unfractionated heparin/warfarin. Therefore, rivaroxaban resulted in a gain of 0.443 quality adjusted life years at an additional cost of $55.661. The incremental cost effectiveness ratios for rivaroxaban compared with warfarin was $125.683 per quality adjusted life year saved which is less than willingness to pay threshold of $783 per quality adjusted life year saved. Warfarin resulted in a net monetary benefit of $11,859.72, while that of rivaroxaban is $12,150.82, meaning rivaroxaban is cost-effective. Sensitivity analyses found that the model was sensitive to utility of no deep vein thrombosis, effectiveness of rivaroxaban and cost of rivaroxaban respectively.Conclusion: This study showed that rivaroxaban is a cost effective alternative and substituting rivaroxaban for warfarin is acceptable to willingness to pay threshold.Keywords: cost effectiveness, DVT, rivaroxaban, warfarin, Ethiopiahttps://www.dovepress.com/a-cost-effectiveness-analysis-of-rivaroxaban-compared-to-warfarin-for--peer-reviewed-fulltext-article-CEORcost effectivenessdvtrivaroxabanwarfarinethiopia |
| spellingShingle | Derseh MT Solomon K Tamene W Beneberu W Yayehrad AT Ambaye AS A Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin for Deep Vein Thrombosis (DVT) Treatment in Ethiopia ClinicoEconomics and Outcomes Research cost effectiveness dvt rivaroxaban warfarin ethiopia |
| title | A Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin for Deep Vein Thrombosis (DVT) Treatment in Ethiopia |
| title_full | A Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin for Deep Vein Thrombosis (DVT) Treatment in Ethiopia |
| title_fullStr | A Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin for Deep Vein Thrombosis (DVT) Treatment in Ethiopia |
| title_full_unstemmed | A Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin for Deep Vein Thrombosis (DVT) Treatment in Ethiopia |
| title_short | A Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin for Deep Vein Thrombosis (DVT) Treatment in Ethiopia |
| title_sort | cost effectiveness analysis of rivaroxaban compared to warfarin for deep vein thrombosis dvt treatment in ethiopia |
| topic | cost effectiveness dvt rivaroxaban warfarin ethiopia |
| url | https://www.dovepress.com/a-cost-effectiveness-analysis-of-rivaroxaban-compared-to-warfarin-for--peer-reviewed-fulltext-article-CEOR |
| work_keys_str_mv | AT dersehmt acosteffectivenessanalysisofrivaroxabancomparedtowarfarinfordeepveinthrombosisdvttreatmentinethiopia AT solomonk acosteffectivenessanalysisofrivaroxabancomparedtowarfarinfordeepveinthrombosisdvttreatmentinethiopia AT tamenew acosteffectivenessanalysisofrivaroxabancomparedtowarfarinfordeepveinthrombosisdvttreatmentinethiopia AT beneberuw acosteffectivenessanalysisofrivaroxabancomparedtowarfarinfordeepveinthrombosisdvttreatmentinethiopia AT yayehradat acosteffectivenessanalysisofrivaroxabancomparedtowarfarinfordeepveinthrombosisdvttreatmentinethiopia AT ambayeas acosteffectivenessanalysisofrivaroxabancomparedtowarfarinfordeepveinthrombosisdvttreatmentinethiopia AT dersehmt costeffectivenessanalysisofrivaroxabancomparedtowarfarinfordeepveinthrombosisdvttreatmentinethiopia AT solomonk costeffectivenessanalysisofrivaroxabancomparedtowarfarinfordeepveinthrombosisdvttreatmentinethiopia AT tamenew costeffectivenessanalysisofrivaroxabancomparedtowarfarinfordeepveinthrombosisdvttreatmentinethiopia AT beneberuw costeffectivenessanalysisofrivaroxabancomparedtowarfarinfordeepveinthrombosisdvttreatmentinethiopia AT yayehradat costeffectivenessanalysisofrivaroxabancomparedtowarfarinfordeepveinthrombosisdvttreatmentinethiopia AT ambayeas costeffectivenessanalysisofrivaroxabancomparedtowarfarinfordeepveinthrombosisdvttreatmentinethiopia |